Approximately 60% of Major Depressive Disorder (MDD) patients do not respond to FDA-approved antidepressants. Introducing effective pharmacotherapies for this treatment-resistant population is hindered by the lack of pre-clinical screening assays that accurately model the clinical features of TRD. The purpose of this research was to screen representatives of different classes FDA-approved antidepressants and one novel antidepressant in two genetic lines of domestic fowl chicks that have previously been identified as stress-vulnerable and stress-resilient in the chick anxiety depression model. Separate groups of socially raised Black Australorp (stress-vulnerable) and Production Red (stress-resilient) chicks were administered the tricyclic antidepressant imipramine (0-20 mg/kg), the selective serotonin reuptake inhibitor (SSRI) fluoxetine (0-10 mg/kg), the tetracyclic antidepressant maprotiline (0-10 mg/kg), the glutamate receptor antagonist ketamine (0-15 mg/kg), or vehicle (physiological saline) and placed individually inside sound attenuating chambers for a 90-minute test period. The behavioral measure of distress vocalizations (DVocs) was recorded via custom designed software. Replication and validation of previous findings of stress sensitivity in the two genetic lines was measured by calculation of the onset of behavioral despair during the depression like phase (30-90 min). Verifying previous research, Black Australorps entered behavioral despair approximately 25% faster than Production Reds signifying the stress-vulnerability of the Black Australorp line. In the depression-like phase, Black Australorps were insensitive to imipramine and fluoxetine, but sensitive to ketamine, a finding that parallels the clinical picture of TRD.
Utilization of the Black Australorps genetic line in the chick anxiety-depression model may be a novel and lone preclinical screening to identify alternative mechanisms and promising leads for TRD.
|Advisor:||Sufka, Kenneth J.|
|Commitee:||Sabol, Karen, Young, John|
|School:||The University of Mississippi|
|School Location:||United States -- Mississippi|
|Source:||MAI 53/06M(E), Masters Abstracts International|
|Subjects:||Neurosciences, Pharmacology, Experimental psychology|
|Keywords:||Depression, Genetic line, Ketamine-sensitive, Treatment-resistant|
Copyright in each Dissertation and Thesis is retained by the author. All Rights Reserved
The supplemental file or files you are about to download were provided to ProQuest by the author as part of a
dissertation or thesis. The supplemental files are provided "AS IS" without warranty. ProQuest is not responsible for the
content, format or impact on the supplemental file(s) on our system. in some cases, the file type may be unknown or
may be a .exe file. We recommend caution as you open such files.
Copyright of the original materials contained in the supplemental file is retained by the author and your access to the
supplemental files is subject to the ProQuest Terms and Conditions of use.
Depending on the size of the file(s) you are downloading, the system may take some time to download them. Please be